<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Vascular involvement is a lethal complication in <z:chebi fb="6" ids="22696">Beh</z:chebi>çet disease </plain></SENT>
<SENT sid="1" pm="."><plain>It is often refractory to conventional therapy such as steroids and <z:chebi fb="1" ids="35705">immunosuppressants</z:chebi> in addition to <z:chebi fb="2" ids="50249">anticoagulants</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>We describe here successful treatment with the anti-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor-alpha (anti-TNF-α) antibody, infliximab, in a patient with <z:chebi fb="6" ids="22696">Beh</z:chebi>çet disease presenting with <z:hpo ids='HP_0002625'>deep vein thrombosis</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>A 60-year-old man with <z:chebi fb="6" ids="22696">Beh</z:chebi>çet disease complained of <z:hpo ids='HP_0000969'>edema</z:hpo> and pain in the lower extremities </plain></SENT>
<SENT sid="4" pm="."><plain>Computed tomography revealed a <z:mp ids='MP_0005048'>thrombosis</z:mp> extending from the popliteal vein to the inferior vena cava at the level of the renal vein and which recurred despite combination therapy of steroid and <z:chebi fb="1" ids="35705">immunosuppressants</z:chebi> such as <z:chebi fb="0" ids="4031">cyclosporine</z:chebi>, <z:chebi fb="2" ids="2948">azathioprine</z:chebi>, and <z:chebi fb="0" ids="44185">methotrexate</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>The patient was then administered infliximab (5 mg/kg) in weeks 0 and 2 and every 4 weeks thereafter </plain></SENT>
<SENT sid="6" pm="."><plain>Clinical and laboratory findings improved after the infliximab therapy </plain></SENT>
<SENT sid="7" pm="."><plain>Computed tomography of the abdomen and lower extremities showed a reduction of the <z:mp ids='MP_0005048'>thrombosis</z:mp> </plain></SENT>
<SENT sid="8" pm="."><plain>No severe adverse events occurred during the clinical course </plain></SENT>
<SENT sid="9" pm="."><plain>Although further studies are needed to confirm the efficacy and safety of its use, anti-TNF-α antibody may be worth considering as treatment for refractory <z:hpo ids='HP_0004936'>venous thrombosis</z:hpo> in patients with <z:chebi fb="6" ids="22696">Beh</z:chebi>çet disease </plain></SENT>
</text></document>